Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | LTA4H | P09960 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5183851 | 0.86 | CES2 (0.73) | ALDH1A1LMNALTA4HKMT2ANPSR1 | |
| SCHEMBL725064 | 0.85 | KMT2A (0.80) | ALDH1A1LMNALTA4HKMT2ASRD5A2 | |
| SCHEMBL822185 | 0.85 | ALDH1A1 (1.00) | ALDH1A1LMNAKMT2ASRD5A2MEN1 | |
| SCHEMBL52200 | 0.85 | ALDH1A1 (1.00) | ALDH1A1LMNAKMT2ASRD5A2MEN1 | |
| Hydrochloric Acid SCHEMBL28795867 | 0.83 | KMT2A (0.76) | ALDH1A1LMNALTA4HKMT2ASRD5A2 | |
| Hydrochloric Acid SCHEMBL27909743 | 0.83 | ALDH1A1 (0.94) | ALDH1A1LMNAKMT2ASRD5A2MEN1 | |
| SCHEMBL11528213 | 0.83 | ALDH1A1 (0.94) | ALDH1A1LMNAKMT2ASRD5A2MEN1 | |
| SCHEMBL13381492 | 0.81 | ALDH1A1 (0.76) | ALDH1A1L3MBTL1RAB9ANPC1PTGS2 | |
| SCHEMBL23332036 | 0.79 | PTGS2 (0.44) | ALDH1A1LMNAKMT2ANPSR1L3MBTL1 | |
| SCHEMBL3522195 | 0.79 | LMNA (0.71) | ALDH1A1LMNALTA4HKMT2ASRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020237991-A1 | THERMALLY ACTIVATED DELAYED FLUORESCENT MOLECULAR MATERIAL, SYNTHESIS METHOD THEREFOR, AND ELECTROLUMINESCENT DEVICE | 武汉华星光电半导体显示技术有限公司 | 2020-12-03 | — | — | WO | disclosed |
| CN-105189485-B | It is used as the novel propylene amide derivatives of anti-malarial agents | 埃科特莱茵药品有限公司 | 2017-10-24 | — | — | CN | disclosed |
| EP-2970217-B1 | NOVEL ACRYLAMIDE DERIVATIVES AS ANTIMALARIAL AGENTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-08-09 | — | — | EP | disclosed |
| US-9637473-B2 | Acrylamide derivatives as antimalarial agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2017-05-02 | — | — | US | disclosed |
| US-20160024050-A1 | NOVEL ACRYLAMIDE DERIVATIVES AS ANTIMALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-01-28 | — | — | US | disclosed |
| EP-2970217-A1 | NOVEL ACRYLAMIDE DERIVATIVES AS ANTIMALARIAL AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2016-01-20 | — | — | EP | disclosed |
| CN-105189485-A | Novel acrylamide derivatives as antimalarial agents | ACTELION PHARMACEUTICALS LTD | 2015-12-23 | — | — | CN | disclosed |
| WO-2014141175-A1 | NOVEL ACRYLAMIDE DERIVATIVES AS ANTIMALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-09-18 | — | — | WO | disclosed |
| EP-2386545-A1 | Heteroaryl ureas containing nitrogen hetero-atoms as P38 kinase inhibitors | Bayer Healthcare LLC (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20080194580-A1 | Inhibition Of Raf Kinase Using Quinolyl, Isoquinolyl Or Pyridyl Ureas | BAYER HEALTHCARE LLC | 2008-08-14 | — | — | US | disclosed |
| US-20080194580-A1 | Inhibition Of Raf Kinase Using Quinolyl, Isoquinolyl Or Pyridyl Ureas | BAYER HEALTHCARE LLC | 2008-08-14 | — | — | US | disclosed |
| US-7371763-B2 | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371763-B2 | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-05-13 | — | — | US | disclosed |
| EP-1379505-B1 | INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS | BAYER PHARMACEUTICALS CORP (US) | 2007-02-28 | — | — | EP | disclosed |
| US-4690931-A | IN TREATMENT OF ANOXIA OR BRAIN DAMAGE | SYNTHELABO (FR) | 1987-09-01 | — | — | US | disclosed |
| EP-0046446-A1 | Polyazaheterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | CIBA-GEIGY AG (CH) | 1982-02-24 | — | — | EP | disclosed |
| US-4128651-A | Bis-quaternary pyridinium-2-aldoxime salts and a process for their preparation | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1978-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194580-A1 | Inhibition Of Raf Kinase Using Quinolyl, Isoquinolyl Or Pyridyl Ureas | BRAF, RAF1, ARAF | ALDH1A1 2722/4885LMNA 2542/4885LTA4H 3690/4885 |
| US-20160024050-A1 | NOVEL ACRYLAMIDE DERIVATIVES AS ANTIMALARIAL AGENTS | RECQL, ACR, ABCC3 | ALDH1A1 375/4885LMNA 2671/4885LTA4H 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.